Substrate reduction therapy is a novel approach to treating glycosphingolipid (GSL) lysosomal storage disorders. These diseases are caused by mutations in the genes coding for enzymes involved in GSL catabolism and are characterised by the accumulation of GSL substrates within the lysosomes of cells. The aim of substrate reduction therapy is to inhibit the rate of synthesis of GSLs to levels where the residual activity of the mutant catabolic enzyme is sufficient to prevent pathological stora...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Substrate reduction therapy for glycosphingolipid storage disorders.
If you are the owner of this record, you can report an update to it here: Report update to this record